Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that selectively activates the growth-hormone secretagogue receptor (GHS-R1a) without measurable activity at receptors associated with cortisol, prolactin, or ACTH release. This selectivity is the experimental signature distinguishing it from earlier secretagogues such as GHRP-2 and GHRP-6.
Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped ~4 days from our lab.
Research applications
GHS-R1a binding affinity and selectivity screens, pituitary GH-release assays, and comparative pharmacokinetics versus GHRP-2/GHRP-6 and natural ghrelin.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
Identity
Parameter
Value
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular formula
C₃₈H₄₉N₉O₅
Molecular weight
711.86 g/mol
CAS number
170851-70-4
Length
5 residues
Quality
Test
Specification
HPLC purity
99.780%
Mass confirmation
ESI-MS within 0.5 Da
Net peptide content
≥ 80% by AAA
Endotoxin
< 0.5 EU/mg (LAL)
Bioburden
< 10 CFU/g
Residual TFA
< 1.0%
Lot LM-2641
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Pure North QC, Canada. Retain samples held under storage spec for five years from release date.
Verification
Method
Result
RP-HPLC at 220 nm
99.41% main peak
ESI-MS (positive)
711.9 Da (theor. 711.86)
Amino acid analysis
82.1% net peptide
LAL endotoxin
< 0.05 EU/mg
Karl Fischer (water)
2.8% w/w
Reconstitution
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Storage after reconstitution
Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Selected references
Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
Howard AD et al. A receptor in pituitary and hypothalamus that functions in GH release. Science. 1996;273(5277):974–977.
Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346–360.
Citing this material
Ipamorelin reference standard, ≥99% (HPLC), Pure North Peptides Inc., Cat. No. LUM-IPA-5, Lot LM-2641.
Ipamorelin is a selective GH secretagogue, classified within the ghrelin-receptor signaling pathway. Structurally it is a pentapeptide GHS-R agonist. Ipamorelin is a synthetic pentapeptide ghrelin-receptor agonist that selectively triggers growth-hormone release without significant effect on cortisol or prolactin. Raun et al. (1998) characterized its pharmacology in rats and beagles.
In an in-vitro setting, Ipamorelin interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable until reconstituted.
Common research applications
In-vitro receptor-binding and dose-response screens against the ghrelin-receptor signaling target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Ipamorelin's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.
Storage & handling
Ipamorelin arrives lyophilized in Canada Post (~4 days). On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
References
Raun K et al. Eur J Endocrinol. 1998;139(5):552-61.
Andersen NB et al. Eur J Pharmacol. 2001;417(3):229-37.
Sinha DK et al. Transl Androl Urol. 2020;9(Suppl 2):S149-59.
For laboratory research only. Ipamorelin is sold strictly as an in-vitro reference standard. Sold as an in-vitro reference standard, not as a Health Canada or FDA-approved therapeutic.